Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353))

Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching P (2021)

Publication Type: Journal article, Erratum

Publication year: 2021

Journal

Annals of Oncology Elsevier

DOI: 10.1016/j.annonc.2021.07.011

Abstract

The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

University of California Los Angeles (UCLA) US United States (USA) (US) British Columbia Cancer Agency CA Canada (CA) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT Italy (IT) Centre Hospitalier Universitaire de Liège (CHU Liège) BE Belgium (BE) Novartis AG CH Switzerland (CH) Highlands Oncology Group US United States (USA) (US) Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL) NL Netherlands (NL) Masaryk Memorial Cancer Institute (MMCI) / Masarykův onkologický ústav (MOÚ) CZ Czech Republic (CZ) Seoul National University (SNU) / 서울대학교 KR Korea, Republic of (KR) Hospitales Universitarios Virgen Macarena y Virgen del Rocío ES Spain (ES) Universidad Complutense de Madrid (UCM) ES Spain (ES) Fondazione IRCCS: Istituto Nazionale dei Tumori IT Italy (IT)

How to cite

APA:

Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.,... Fasching, P. (2021). Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)). Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.07.011

MLA:

Slamon, D. J., et al. "Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353))." Annals of Oncology (2021).

BibTeX: Download